Section Arrow
CRDF.NASDAQ
- Cardiff Oncology
Quotes are at least 15-min delayed:2024/05/15 18:41 EDT
Last
 3.57
-0.01 (-0.28%)
Day High 
3.75 
Prev. Close
3.58 
1-M High
5.66 
Volume 
336.26K 
Bid
3.57
Ask
3.84
Day Low
3.525 
Open
3.59 
1-M Low
3.11 
Market Cap 
160.11M 
Currency USD 
P/E -- 
%Yield
10-SMA 3.6 
20-SMA 3.94 
50-SMA 4.67 
52-W High 6.42 
52-W Low 0.94 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.90/-0.98
Enterprise Value
161.57M
Balance Sheet
Book Value Per Share
1.36
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
488.00K
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/15 18:41 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.